GENOME BIOLOGICS
Genome Biologics are leaders in therapeutic target discovery and RNA-targeted therapies in cardiovascular and cardiometabolic disease. Our technology platforms seamlessly integrate synergistically to accelerate development of RNAi therapies to treat illnesses where no other treatments have proven effective or ever existed.
GENOME BIOLOGICS
Industry:
Biotechnology Genetics Pharmaceutical Therapeutics
Founded:
2017-01-01
Address:
Hessen, Sachsen-Anhalt, Germany
Country:
Germany
Website Url:
http://www.genomebiologics.come
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.47 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Euro Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS GoDaddy DNS
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Imara
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
Inception Sciences
Inception Sciences creates therapies with transformative potential to address diseases and disorders with significant unmet need.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Oxford BioMedica
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Current Employees Featured
Founder
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Genome Biologics
Official Site Inspections
http://www.genomebiologics.come
Unable to get host informations!!!
More informations about "Genome Biologics"
Genome Biologics
Genome Biologics is a resident company of Johnson & Johnson Innovation - JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, …See details»
Our team - Genome Biologics
Our mission is to identify novel cardiac therapies through targeting of the disease transcriptome. Founded in 2016, Genome Biologics won the EIC SME Instrument Phase 1 and the German …See details»
Genome Biologics - Crunchbase Company Profile & Funding
Genome Biologics are leaders in therapeutic target discovery and RNA-targeted therapies in cardiovascular and cardiometabolic disease. Our technology platforms seamlessly integrate …See details»
Drug Development, Drug Positioning - Genome Biologics
Pressure on drug pipelines from the patent cliff and a relative scarcity of new chemical entities. More stringent regulatory requirements, driving the need for real value-add in new products …See details»
Contact Us - Genome Biologics
Info[at]genomebiologics.com. Laboratories & Offices. Headquarters Headquarters Headquarters. Genome Biologics. Centre for Molecular Medicine. Goethe-University Frankfurt. Theodor-Stern …See details»
Genome Biologics - LinkedIn
Genome Biologics identifies viable drug candidates and FDA approved drug repositioning compounds for Cardiovascular and Cardiometabolic disease.See details»
Genome Biologics - Overview, News & Similar companies
Genome Biologics contact info: Phone number: +49 69630187961 Website: www.genomebiologics.com What does Genome Biologics do? Genome Biologics is a resident …See details»
Genome Biologics - PitchBook
Publication ID Patent Title Status First Filing Date Technology (CPC) Citations; EP-4215195-A1: Lanatoside c, clopidogrel, and r406 in treatment of cvd-clonal hematopoiesis of indeterminate …See details»
Redefining Drug Development | Genome Biologics
AI driven preclinical disease modeling. TEL: +49 (0) 69 950 141 92. TEL: +49 (0) 176 227 686 00. [email protected]See details»
Genome Biologics - Craft
Genome Biologics is a biotech company developing an AI-based preclinical multi-modality drug testing technology called GENIMAPS. It allows scientists to identify viable drug candidates and …See details»
Genome Biologics Information - RocketReach
Genomebiologics.com; 4 659144XXXX; 44797951XXXX; 44156478XXXX; 44156478XXXX; Maria Duda Chief Operating Officer at Genome Biologics Frankfurt, HE, DE View. 2 zs.com; …See details»
Genome Biologics - LinkedIn
Genome Biologics is a Biotherapeutics company headquartered in Germany with a strong background and proven track record in in silico drug screening, in vivo preclinical drug testing …See details»
GENOME BIOLOGICS UG - VentureRadar
"We are leaders in therapeutic target discovery and RNA-targeted therapies in cardiovascular and cardiometabolic disease. Our technology platforms seamlessly integrate synergistically to …See details»
Genome Biologics - Products, Competitors, Financials, Employees ...
Genomebiologics.com. Overview & Products; Financials; People; Founded Year 2016. Stage Incubator/Accelerator | Alive. Mosaic Score. The Mosaic Score is an algorithm that measures …See details»
GENOME BIOLOGICS UG - explore.openaire.eu
Organization, country, GENOME BIOLOGICS UGGENOME BIOLOGICS UGSee details»
GenBio - F6S
Genomebiologics.com. About GenBio. We have established an integrated drug discovery and validation platform, consisting of 3 technologies; an AI-driven computational platform …See details»
Press Release - Genome Biologics
Genome Biologics is a resident company of Johnson & Johnson Innovation - JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, …See details»
Technology behind the pipeline - Genome Biologics
GENIMAPS® and GENISYST® technology integration facilitates Ai-driven target and drug identification, and direct therapeutic validation in vitro (2D and 3D), and in small and large …See details»
Building Biobanks to Drive Biomedical Research and Genomically …
Over the last decade, an increasing number of biobanks have been created, many launched at the national level in countries around the world 1 as well as in independent health care …See details»
Therapies - Genome Biologics
Kearns-Sayre Syndrome (KSS) is a mitochondrial disease, with Rare Disease designation (7,400 – 22,000 patients in Europe), caused primarily by large-scale mitochondrial DNA deletions.See details»